| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurological Sciences (Drs. Meriggioli and Rowin), Rush University, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL; the Department of Neurology (Dr. Ciafaloni), University of Rochester School of Medicine, NY; and the Division of Neurology (Drs. Al-Hayk, Massey, and Sanders, and B. Tucker-Lipscomb), Duke University Medical Center, Durham, NC.
Address correspondence and reprint requests to Dr. Matthew N. Meriggioli, Rush University, Dept. of Neurological Sciences, 1725 W. Harrison Street, Suite 1106, Chicago, IL 60612; e-mail: Matthew_N_Meriggioli{at}rush.edu
The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.
Received May 28, 2003. Accepted in final form July 26, 2003.
*These authors contributed equally to this work.
Presented at the annual meeting of the American Academy of Neurology; April 3, 2003.
This article has been cited by other articles:
|
|
 |
|
  A. Jacob, M. Matiello, B. G. Weinshenker, D. M. Wingerchuk, C. Lucchinetti, E. Shuster, J. Carter, B. M. Keegan, O. H. Kantarci, and S. J. Pittock Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients Arch Neurol, September 1, 2009; 66(9): 1128 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Benatar and L. P. Rowland The muddle of mycophenolate mofetil in myasthenia Neurology, August 5, 2008; 71(6): 390 - 391. [Full Text] [PDF]
|
|
|
|
|
|
The Muscle Study Group A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis Neurology, August 5, 2008; 71(6): 394 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Sanders, I. K. Hart, R. Mantegazza, S. S. Shukla, Z. A. Siddiqi, M.H.V. De Baets, A. Melms, M. W. Nicolle, N. Solomons, and D. P. Richman An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis Neurology, August 5, 2008; 71(6): 400 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Piepers, R. Van den Berg-Vos, W-L. Van der Pol, H. Franssen, J. Wokke, and L. Van den Berg Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial Brain, August 1, 2007; 130(8): 2004 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D Cahoon Jr and D. R Kockler Mycophenolate Mofetil Treatment of Myasthenia Gravis Ann. Pharmacother., February 1, 2006; 40(2): 295 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vernino, D. R. Salomao, T. M. Habermann, and B. P. O'Neill Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil Neurology, August 23, 2005; 65(4): 639 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Bedlack, D. L. Simel, H. Bosworth, G. Samsa, B. Tucker-Lipscomb, and D. B. Sanders Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity Neurology, June 14, 2005; 64(11): 1968 - 1970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Ciafaloni Mycophenolate mofetil and myasthenia gravis Lupus, March 1, 2005; 14(3_suppl): s46 - s49. [Abstract] [PDF]
|
|
|
|
|
|
E. Ciafaloni Mycophenolate mofetil and myasthenia gravis Lupus, January 1, 2005; 14(1_suppl): s46 - s49. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
